BioSenic S.A. - Asset Resilience Ratio
BioSenic S.A. (BIOS) has an Asset Resilience Ratio of -3.43% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BIOS total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2023)
This chart shows how BioSenic S.A.'s Asset Resilience Ratio has changed over time. See BIOS book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down BioSenic S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BioSenic S.A. stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €-322.00K | -3.43% |
| Total Liquid Assets | €-322.00K | -3.43% |
Asset Resilience Insights
- Limited Liquidity: BioSenic S.A. maintains only -3.43% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
BioSenic S.A. Industry Peers by Asset Resilience Ratio
Compare BioSenic S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for BioSenic S.A. (2011–2023)
The table below shows the annual Asset Resilience Ratio data for BioSenic S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 4.16% | €398.00K ≈ $465.30K |
€9.56 Million ≈ $11.18 Million |
+4.54pp |
| 2022-12-31 | -0.38% | €-111.00K ≈ $-129.77K |
€29.32 Million ≈ $34.28 Million |
-6.45pp |
| 2021-12-31 | 6.07% | €1.20 Million ≈ $1.40 Million |
€19.77 Million ≈ $23.12 Million |
+6.69pp |
| 2019-12-31 | -0.63% | €-140.00K ≈ $-163.67K |
€22.39 Million ≈ $26.18 Million |
-1.97pp |
| 2011-12-31 | 1.35% | €203.00K ≈ $237.33K |
€15.05 Million ≈ $17.60 Million |
-- |
About BioSenic S.A.
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Pha… Read more